Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
112 studies found for:    Open Studies | HIV or AIDS | NIAID
Show Display Options
Rank Status Study
1 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
2 Unknown  Resistance to HIV Infection
Condition: HIV Infections
Intervention:
3 Recruiting Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
Conditions: HIV Infections;   AIDS;   Opportunistic Infections
Intervention:
4 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
5 Recruiting Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Conditions: Acquired Immune Deficiency Syndrome Virus;   Acquired Immunodeficiency Syndrome Virus;   AIDS Virus;   Human Immunodeficiency Virus;   Human Immunodeficiency Viruses
Intervention:
6 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
7 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
8 Not yet recruiting Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01;   Drug: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
9 Not yet recruiting Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
10 Unknown  Women's Interagency HIV Study (WIHS)
Condition: HIV Infections
Intervention:
11 Not yet recruiting Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Condition: HIV Infections
Interventions: Drug: Maraviroc;   Drug: Placebo
12 Recruiting Evaluating the Safety and Pharmacokinetics of VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants
Condition: HIV Infections
Intervention: Biological: VRC01
13 Not yet recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
14 Not yet recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
15 Recruiting Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Children Infected With HIV and TB
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: Raltegravir
16 Recruiting Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Efavirenz;   Drug: Raltegravir
17 Recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
18 Not yet recruiting Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Maraviroc
19 Recruiting Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at High Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Raltegravir
20 Recruiting Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Condition: HIV Infections
Interventions: Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years